Development of domestic multiplex gene panel test for cancer personalized medicine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1062200037

Enrollment

250

Registered

2020-12-21

Start date

2020-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid cancers

Interventions

TSO500 is an unapproved diagnostic test, and the test results will be potentially used for the treatment decision making. Therefore, it is treated as "research with intervention".

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age : 16-year-old or more. 2) Performance Status (ECOG criteria) : 0 or 1 3) Histologically proven solid cancers available for the tissues with enough tumor contents. 4) Solid cancers (including cancer of unknown primary ) with unresectable and relapse disease, that 1) do not have standard treatment, 2) have completed or are expected to complete standard treatment. 5) Written informed consent

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in the study

Design outcomes

Primary

Measure	Time frame
The detection rate of actionable genetic alterations	—

Secondary

Measure	Time frame
The successful rate of sequencing The treatment rate of the actionable drugs The concordance rate of the results between panels	—

Contacts

Public ContactShuta Tomida

Okayama University Hospital

shuta.tomida@okayama-u.ac.jp+81-86-235-7414

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026